tirzepatide alzheimer's trial Read now: The SURPASS-EARLY found that starting #tirzepatide early in #type2diabetes led to greater improvements in blood sugar, body weight, and waist size than intensified standard care. https://bit.ly/3RWnB8m Could diabetes and weight loss
Description
Tirzepatides dual-action mechanism targets both the GLP-1 and GIP receptors, making it a powerful tool in diabetes management
Retatrutide shows slightly higher potential (~ 24 %), but the difference is small compared to waiting years for treatment
It is marketed as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management
Individual responses range from 15 to 30 percent weight loss, with higher responders typically being those who implement comprehensive lifestyle modifications alongside medication use
CoreAge RX is $149 flat on an annual term, and Trimi is about $125
Costs are a concern with these drugs, but coupons for Mounjaro and Zepbound and a SingleCare prescription discount card can help
